These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30839008)

  • 1. Comparative antitumor studies of organoruthenium complexes with 8-hydroxyquinolines on 2D and 3D cell models of bone, lung and breast cancer.
    Ruiz MC; Kljun J; Turel I; Di Virgilio AL; León IE
    Metallomics; 2019 Mar; 11(3):666-675. PubMed ID: 30839008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological characterization of organoruthenium complexes with 8-hydroxyquinolines.
    Kljun J; León IE; Peršič Š; Cadavid-Vargas JF; Etcheverry SB; He W; Bai Y; Turel I
    J Inorg Biochem; 2018 Sep; 186():187-196. PubMed ID: 29960150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer and antimetastatic activity of copper(II)-tropolone complex against human breast cancer cells, breast multicellular spheroids and mammospheres.
    Balsa LM; Ruiz MC; Santa Maria de la Parra L; Baran EJ; León IE
    J Inorg Biochem; 2020 Mar; 204():110975. PubMed ID: 31911364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer activity of a new copper(II) complex with a hydrazone ligand. Structural and spectroscopic characterization, computational simulations and cell mechanistic studies on 2D and 3D breast cancer cell models.
    Balsa LM; Ferraresi-Curotto V; Lavecchia MJ; Echeverría GA; Piro OE; García-Tojal J; Pis-Diez R; González-Baró AC; León IE
    Dalton Trans; 2021 Jul; 50(28):9812-9826. PubMed ID: 34190268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ruthenium complexes cis-(dichloro)tetramineruthenium(III) chloride and cis-tetraammine(oxalato)ruthenium(III) dithionate overcome resistance inducing apoptosis on human lung carcinoma cells (A549).
    Vilanova-Costa CA; Porto HK; Pereira Fde C; de Lima AP; Dos Santos WB; Silveira-Lacerda Ede P
    Biometals; 2014 Jun; 27(3):459-69. PubMed ID: 24781824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly Cytotoxic Ruthenium(II)-Arene Complexes from Bulky 1-Pyrenylphosphane Ligands.
    Brissos RF; Clavero P; Gallen A; Grabulosa A; Barrios LA; Caballero AB; Korrodi-Gregório L; Pérez-Tomás R; Muller G; Soto-Cerrato V; Gamez P
    Inorg Chem; 2018 Dec; 57(23):14786-14797. PubMed ID: 30444630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin.
    Meier SM; Kreutz D; Winter L; Klose MHM; Cseh K; Weiss T; Bileck A; Alte B; Mader JC; Jana S; Chatterjee A; Bhattacharyya A; Hejl M; Jakupec MA; Heffeter P; Berger W; Hartinger CG; Keppler BK; Wiche G; Gerner C
    Angew Chem Int Ed Engl; 2017 Jul; 56(28):8267-8271. PubMed ID: 28547791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
    Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI
    Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of anticancer role of a novel ruthenium(II)-based compound compared with NAMI-A and cisplatin in impairing mitochondrial functionality and promoting oxidative stress in triple negative breast cancer models.
    Silvestri S; Cirilli I; Marcheggiani F; Dludla P; Lupidi G; Pettinari R; Marchetti F; Di Nicola C; Falcioni G; Marchini C; Orlando P; Tiano L; Amici A
    Mitochondrion; 2021 Jan; 56():25-34. PubMed ID: 33220497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of organoruthenium complexes with chelate aromatic ligands, derived from 1,10-phenantroline: Synthesis and biological activity.
    Savić A; Gligorijević N; Aranđelović S; Dojčinović B; Kaczmarek AM; Radulović S; Van Deun R; Van Hecke K
    J Inorg Biochem; 2020 Jan; 202():110869. PubMed ID: 31669694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel tetranuclear ruthenium(II) arene complexes showing potent cytotoxic and antimetastatic activity as well as low toxicity in vivo.
    Mohamed Subarkhan MK; Ren L; Xie B; Chen C; Wang Y; Wang H
    Eur J Med Chem; 2019 Oct; 179():246-256. PubMed ID: 31255925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative solution equilibrium studies of antitumor ruthenium(η
    Dömötör O; Pape VFS; May NV; Szakács G; Enyedy ÉA
    Dalton Trans; 2017 Mar; 46(13):4382-4396. PubMed ID: 28287667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between 8-hydroxyquinoline ruthenium(II) complexes and basic fibroblast growth factors (bFGF): inhibiting angiogenesis and tumor growth through ERK and AKT signaling pathways.
    Yang L; Zhang J; Wang C; Qin X; Yu Q; Zhou Y; Liu J
    Metallomics; 2014 Mar; 6(3):518-31. PubMed ID: 24336978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
    Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
    Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Labile ruthenium(ii) complexes with extended phenyl-substituted terpyridyl ligands: synthesis, aquation and anticancer evaluation.
    Huang H; Zhang P; Chen Y; Ji L; Chao H
    Dalton Trans; 2015 Sep; 44(35):15602-10. PubMed ID: 26245234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer activity of two novel ruthenium compounds in gastric cancer cells.
    Ramírez-Rivera S; Pizarro S; Gallardo M; Gajardo F; Delgadillo A; De La Fuente-Ortega E; MacDonnell FM; Bernal G
    Life Sci; 2018 Nov; 213():57-65. PubMed ID: 30326218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bifunctional organometallic ruthenium drug with multiple modes of inducing apoptosis.
    Chatterjee S; Biondi I; Dyson PJ; Bhattacharyya A
    J Biol Inorg Chem; 2011 Jun; 16(5):715-24. PubMed ID: 21437708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the In Vitro and In Vivo Efficacy of Ruthenium Polypyridyl Compounds against Breast Cancer.
    Lenis-Rojas OA; Roma-Rodrigues C; Fernandes AR; Carvalho A; Cordeiro S; Guerra-Varela J; Sánchez L; Vázquez-García D; López-Torres M; Fernández A; Fernández JJ
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between polypyridyl and cyclometalated ruthenium(II) complexes: anticancer activities against 2D and 3D cancer models.
    Huang H; Zhang P; Chen H; Ji L; Chao H
    Chemistry; 2015 Jan; 21(2):715-25. PubMed ID: 25388328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New organoruthenium compounds with pyrido[2',3':5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action.
    Pavlović M; Nikolić S; Gligorijević N; Dojčinović B; Aranđelović S; Grgurić-Šipka S; Radulović S
    J Biol Inorg Chem; 2019 Mar; 24(2):297-310. PubMed ID: 30762123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.